123 related articles for article (PubMed ID: 18521799)
21. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma.
Kim J; Lee YS; Hwang IK; Kang BK; Cho JY; Yoon YS; Han HS; Hwang JH
J Korean Med Sci; 2015 Mar; 30(3):259-63. PubMed ID: 25729247
[TBL] [Abstract][Full Text] [Related]
22. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
Ozkan H; Kaya M; Cengiz A
Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813
[TBL] [Abstract][Full Text] [Related]
23. Serum CA 242 in pancreatic cancer. Comparison with CA 19-9 and CEA.
Pezzilli R; Billi P; Plate L; Laudadio MA; Sprovieri G
Ital J Gastroenterol; 1995; 27(6):296-9. PubMed ID: 8562994
[TBL] [Abstract][Full Text] [Related]
24. CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice.
Duraker N; Hot S; Polat Y; Höbek A; Gençler N; Urhan N
J Surg Oncol; 2007 Feb; 95(2):142-7. PubMed ID: 17262731
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic value of tissue polypeptide specific antigen in patients with pancreatic carcinoma.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Tumour Biol; 1994; 15(1):52-60. PubMed ID: 8146530
[TBL] [Abstract][Full Text] [Related]
26. Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology.
Ferri MJ; Saez M; Figueras J; Fort E; Sabat M; López-Ben S; de Llorens R; Aleixandre RN; Peracaula R
PLoS One; 2016; 11(1):e0147214. PubMed ID: 26808421
[TBL] [Abstract][Full Text] [Related]
27. Stem cell factor and macrophage-colony stimulating factor in patients with pancreatic cancer.
Mroczko B; Szmitkowski M; Wereszczynska-Siemiatkowska U; Jurkowska G
Clin Chem Lab Med; 2004 Mar; 42(3):256-60. PubMed ID: 15080556
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
[TBL] [Abstract][Full Text] [Related]
29. Precystectomy serum levels of carbohydrate antigen 19-9, carbohydrate antigen 125, and carcinoembryonic antigen: prognostic value in invasive urothelial carcinoma of the bladder.
Ahmadi H; Djaladat H; Cai J; Miranda G; Daneshmand S
Urol Oncol; 2014 Jul; 32(5):648-56. PubMed ID: 24680660
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic validity of serum macrophage inhibitor cytokine and tissue polypeptide-specific antigen in pancreatobiliary diseases.
Ozkan H; Demirbaş S; Ibiş M; Akbal E; Köklü S
Pancreatology; 2011; 11(3):295-300. PubMed ID: 21757969
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic value of carcinoembryonic antigen and carcinoma antigen 19-9 for colorectal carcinoma.
Zhang SY; Lin M; Zhang HB
Int J Clin Exp Pathol; 2015; 8(8):9404-9. PubMed ID: 26464695
[TBL] [Abstract][Full Text] [Related]
32. Combination of tumour markers CEA and CA19-9 improves the prognostic prediction in patients with pancreatic cancer.
Reitz D; Gerger A; Seidel J; Kornprat P; Samonigg H; Stotz M; Szkandera J; Pichler M
J Clin Pathol; 2015 Jun; 68(6):427-33. PubMed ID: 25759406
[TBL] [Abstract][Full Text] [Related]
33. Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies.
Mehta J; Prabhu R; Eshpuniyani P; Kantharia C; Supe A
Trop Gastroenterol; 2010; 31(3):190-4. PubMed ID: 21560524
[TBL] [Abstract][Full Text] [Related]
34. CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer.
Griesenberg D; Nürnberg R; Bahlo M; Klapdor R
Anticancer Res; 1999; 19(4A):2443-50. PubMed ID: 10470173
[TBL] [Abstract][Full Text] [Related]
35. Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
Anticancer Res; 1995; 15(6B):2731-7. PubMed ID: 8669855
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic and prognostic values of CA 19-9 and CEA in periampullary cancers.
Kau SY; Shyr YM; Su CH; Wu CW; Lui WY
J Am Coll Surg; 1999 Apr; 188(4):415-20. PubMed ID: 10195726
[TBL] [Abstract][Full Text] [Related]
37. Tumor markers in evaluating the response to radiotherapy in unresectable pancreatic cancer.
Okusaka T; Okada S; Sato T; Wakasugi H; Saisho H; Furuse J; Ishikawa O; Matsuno S; Yokoyama S
Hepatogastroenterology; 1998; 45(21):867-72. PubMed ID: 9684148
[TBL] [Abstract][Full Text] [Related]
38. [Accuracy of imaging techniques and tumor markers in the diagnosis of pancreatic cancer].
Clavé P; Boadas J; González-Carro P; Mora J; Pérez C; Martínez A; Roca M; Lluís F; Farré A
Gastroenterol Hepatol; 1999; 22(7):335-41. PubMed ID: 10535205
[TBL] [Abstract][Full Text] [Related]
39. The value of combined use of serum tumour markers and nuclear magnetic spectroscopy of plasma in the detection of pancreatic cancer among patients with jaundice or cholestasis: results from a prospective study.
Pasanen PA; Kauppinen R; Eskelinen M; Partanen K; Pikkarainen P; Alhava E
Anticancer Res; 1993; 13(3):763-8. PubMed ID: 8317910
[TBL] [Abstract][Full Text] [Related]
40. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?
Kim YC; Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Shin JH
J Gastroenterol Hepatol; 2009 Dec; 24(12):1869-75. PubMed ID: 19686409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]